An interventional study of Politix Fiber arm in Chronic Wound Care, Local Infection and Safety, sponsored by Sebastian Probst. Not yet recruiting at 3 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Sebastian Probst · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
You can paste the following into the **Brief Summary** field: POLTX_CIP_template_e_klinv-mep\_…
The goal of this study is to learn about the safety, wound healing, and ease of use of POLTX_Fiber, an absorbent wound dressing that forms a gel when it takes up wound fluid. The study will include approximately 60 adults receiving outpatient care in Switzerland. Participants will have wounds that have been present for at least four weeks and produce moderate to large amounts of fluid. These may include venous leg ulcers, diabetic foot ulcers, pressure ulcers, or ulcers with more than one cause.
The main questions are:
Participants will receive either POLTX_Fiber or Suprasorb Liquacel Pro, another absorbent wound dressing. Dressing assignment will follow a predefined schedule rather than chance. Participants and their care teams will know which dressing is used. Results for each dressing group will be described separately.
Participants will:
After the study treatment ends, participants will receive wound dressings prescribed by their care team. Each participant will take part for 12 weeks.
This investigator-initiated, multicentre, open-label, non-randomized post-market clinical follow-up study will characterize the short-term safety, clinical performance, and usability of POLTX_Fiber under routine outpatient wound-care conditions. POLTX_Fiber is a CE-marked absorbent gelling fibre dressing used according to the manufacturer's instructions for use.
Consecutive eligible patients will be enrolled at participating centres. Following confirmation of eligibility and written informed consent, participants will be allocated in a 1:1 ratio to POLTX_Fiber or Suprasorb Liquacel Pro using a predefined, non-randomized sequential allocation schedule implemented separately at each site in REDCap. Assignment will not depend on wound characteristics, clinical suitability, or investigator preference. The Suprasorb Liquacel Pro group will provide contextual information on outcomes observed with an established dressing.
Both groups will continue appropriate care for the underlying wound condition. Dressing changes will follow the applicable instructions for use and clinical needs. Changes in treatment or early discontinuation for clinical reasons will be documented, including their rationale.
Wound area will be measured using digital planimetry. Standardized wound photographs will support central review of wound healing, tissue composition, and the condition of the surrounding skin. Although participants and treating clinicians will know the assigned dressing, central wound-image assessors will remain unaware of treatment allocation. Safety surveillance will include adverse events, events considered related to the dressings, and device deficiencies throughout participation.
Analyses will be descriptive and exploratory. Outcomes will be summarized separately for each dressing group using appropriate descriptive statistics. Where informative, confidence intervals will describe the precision of estimates. No formal between-group hypothesis testing is planned, and the study is not designed to establish superiority, non-inferiority, or equivalence between the dressings. Missing data will not be imputed; available observations and missing assessments will be reported.
Sebastian Probst is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
POLTX\_Fiber, an absorbent gelling fiber dressing for moderate-high exudate chronic wounds
Combination Product: Politix Fiber arm
Suprasorb® Liquacel Pro arm
Combination Product: Politix Fiber arm
POLTX\_Fiber is a CE-marked absorbent gelling fibre wound dressing. It absorbs wound fluid and forms a gel to maintain a moist wound environment. The dressing will be applied directly to the study wound according to the manufacturer's instructions for use for up to 30 days or until wound closure, whichever occurs first. Dressing changes will depend on wound fluid levels and clinical needs. Participants will continue standard care for the underlying wound condition.
Incidence of adverse events and device deficiencies
Number and percentage of participants experiencing adverse events, including serious adverse events and events considered related to the study dressing. Events will be characterized by seriousness, severity, expectedness, relationship to the dressing, action taken, and clinical outcome. Device deficiencies, such as dressing fragmentation or fibres remaining in the wound, will also be recorded and summarized. Results will be reported separately for each dressing group.
Time frame: 12 Weeks
Percentage wound area reduction from baseline to Day 30
Percentage change in study wound area, measured using imitoWound digital planimetry. Percentage wound area reduction will be calculated as: \[(baseline wound area - Day 30 wound area) / baseline wound area\] × 100. Positive values indicate a reduction in wound size; negative values indicate an increase. Results will be summarized separately for each dressing group.
Time frame: Baseline to Day 30 (±1 day).
Proportion of POLTX_Fiber dressing removals completed in one piece
At each assessed POLTX\_Fiber dressing removal, the clinician will record whether the dressing was completely removed in one piece (yes/no). For each participant receiving POLTX\_Fiber, the number of removals completed in one piece will be divided by the total number of assessed removals and expressed as a percentage. These participant-level percentages will be summarized descriptively. The number of assessed removals and missing assessments will also be reported.
Time frame: Baseline through Day 30 (±1 day).
Percentage wound area reduction at Weeks 1, 2, 3, 8 and 12
Percentage wound area reduction from baseline to each specified visit, measured using imitoWound digital planimetry. The percentage will be calculated as: \[(baseline wound area - wound area at the assessment visit) / baseline wound area\] × 100. Positive values indicate a reduction in wound size; negative values indicate an increase. Results will be summarized separately for each dressing group and visit.
Time frame: 12 weeks
Change in wound tissue composition
Change from baseline in the percentage of the wound area covered by epithelial tissue, granulation tissue, slough/fibrin, and necrotic tissue, assessed using imitoWound digital wound imaging. Each tissue type will be expressed as a percentage of the total wound area. Changes will be reported in percentage points and summarized separately for each dressing group and visit.
Time frame: 12 weeks
Change from baseline in the condition of the skin surrounding the wound
Condition of the skin surrounding the study wound, assessed using standardized digital wound images and documented as healthy, macerated (softened or damaged by excess moisture), or erythematous (red). Changes from the baseline category will be summarized descriptively, with the number and percentage of participants in each category reported separately for each dressing group and visit.
Time frame: 12 weeks
Local infection signs
Local infection signs will be assessed using the TILI, recording six indirect criteria and three direct criteria. Change from baseline in the number of indirect criteria present (range: 0-6; higher values indicate more signs of local infection) will be summarized. The number and percentage of participants meeting the TILI criteria for antimicrobial wound treatment-at least five indirect criteria or at least one direct criterion-will also be reported. Results will be summarized separately for each dressing group and visit. TILI supports clinical assessment and does not independently establish a diagnosis of wound infection.
Time frame: 12 weeks
Investigator assessment of dressing usability and handling
Usability and handling of POLTX\_Fiber will be assessed using the French version of the Investigator Usability and Handling Questionnaire (IUHQ). Items assess ease of application, comfort during application, ease of removal, and overall satisfaction. Each item uses a five-point scale, with higher ratings indicating a more favourable assessment. Responses will be summarized separately for each item and visit. Dressing integrity upon removal is reported separately as a primary outcome.
Time frame: Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
Pain intensity before and after dressing changes
Participants will rate pain intensity immediately before and after dressing changes using a 10-cm visual analogue scale, ranging from 0 (no pain) to 10 (worst pain imaginable). Higher scores indicate greater pain intensity. Scores before and after dressing changes will be summarized separately for each dressing group and visit.
Time frame: Baseline and Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
Change from baseline in wound exudate amount
Wound fluid (exudate) amount will be assessed before wound cleansing using the exudate amount item of the Bates-Jensen Wound Assessment Tool. Scores range from 1 (none) to 5 (large), with higher scores indicating more wound fluid. Changes from baseline and the number and percentage of participants in each category will be summarized separately for each dressing group and visit.
Time frame: 12 weeks
Change from baseline in wound exudate colour
Wound fluid (exudate) colour will be assessed by the investigator and categorized as serous (clear/amber), serosanguinous (pink), or purulent (opaque/yellow/green). Changes from the baseline category and the number and percentage of participants in each category will be summarized separately for each dressing group and visit.
Time frame: 12 weeks
Change from baseline in wound exudate odour
Wound fluid (exudate) odour will be assessed by the investigator and categorized as absent, faint, moderate, or strong. Changes from the baseline category and the number and percentage of participants in each category will be summarized separately for each dressing group and visit.
Time frame: 12 weeks
Frequency of dressing changes during the treatment period
The total number of scheduled and unscheduled dressing changes will be recorded for each participant during the treatment period. Participants will be categorized by dressing-change frequency as ≤2, 3-4, or ≥5 changes per week. Total dressing counts and frequency categories will be summarized separately for each dressing group.
Time frame: Baseline through Day 30 (±1 day).
Patient-reported global tolerability of the dressing
Participants will independently rate dressing tolerability using a three-point scale: 0 = no issues, 1 = moderate tolerability, and 2 = poor tolerability. Higher scores indicate poorer tolerability. The number and percentage of participants selecting each response will be summarized separately for each dressing group and visit.
Time frame: Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
Plan to share: Yes — Raw data will be shared using Yareta (https://yareta.unige.ch/home) a Swiss research platform using the FAIR priniples
Supporting information: Analytic code
Time frame: from 2028 until 2029
Access criteria: all researchers
Data sharing details ↗ · yareta.unige.ch
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Oct 2027, 10 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Jun 2026 → Dec 2026, primary completion Jun 2027 → Oct 2027 and completion Sep 2027 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sebastian Probst